- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04677452
Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
An Open-Label Phase 1 Dose Exploration Study of JWCAR129, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- First Affiliated Hospital, SooChow University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years old and above.
- Signed the Informed Consent Form.
Diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Subjects must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen). Subjects must be refractory to the last anti-myeloma treatment regimen prior to entering the study.
- Autologous hematopoietic stem cell transplantation.
- A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination. Subjects must have undergone at least 2 consecutive cycles of treatment for each regimen unless progressive disease was the best response to the regimen.
- Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy.
Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible; the reason for not receiving treatment must be clearly documented in the case report form.
- Subjects must have measurable disease.
- Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function
Exclusion Criteria:
- Subjects with known active or history of CNS involvement by malignancy
- Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis
- History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.
- Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])
- Prior CAR T-cell or other genetically-modified T-cell therapy
- Prior treatment with a BCMA-targeted agent
- History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
- Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JWCAR129 infusion.
- History of any of the following cardiovascular conditions within 6 months of initial screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease
- History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study
- Allogeneic hematopoietic stem cell transplantation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JWCAR129
Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
|
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129.
During JWCAR129 production, participants may receive bridging chemotherapy for disease control.
Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose-limiting toxicities (DLTs)
Time Frame: 28 days
|
Proportion of subjects with adverse events meeting DLT criteria
|
28 days
|
Incidence and severity of adverse events
Time Frame: 2 years
|
Proportion of subjects with adverse events overall and by severity grade
|
2 years
|
Incidence and severity of clinically significant laboratory abnormalities
Time Frame: 2 years
|
Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: 2 years
|
Maximum concentration (Cmax) of JWCAR129 in the blood
|
2 years
|
Tmax
Time Frame: 2 years
|
Time to maximum concentration (Tmax) of JWCAR129 in the blood
|
2 years
|
AUC
Time Frame: 2 years
|
Area under the concentration vs time curve (AUC) of JWCAR129 in the blood
|
2 years
|
Duration of persistence
Time Frame: 2 years
|
Duration of persistence of JWCAR129 CAR T cells in the blood
|
2 years
|
Overall response rate
Time Frame: 2 years
|
Proportion of subjects with a partial response (PR) or better by IMWG criteria
|
2 years
|
CR rate
Time Frame: 2 years
|
Proportion of subjects with a CR by IMWG criteria
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- JWCAR129
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety and Efficacy
-
Qianfoshan HospitalActive, not recruiting
-
Cutia Therapeutics(Wuxi)Co.,LtdRecruiting
-
Yonsei UniversityRecruiting
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
Vedic Lifesciences Pvt. Ltd.CompletedSafety and EfficacyIndia
-
Guizhou Medical UniversityUnknown
-
Shanghai Jiao Tong University School of MedicineNot yet recruiting
-
Sichuan Huiyu Pharmaceutical Co., LtdRecruitingEfficacy | Tolerability | SafetyChina
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.The First Hospital of Jilin UniversityRecruitingPharmacokinetics | Efficacy | SafetyChina
-
Erasme University HospitalTerminatedEfficacy | Anesthesia | Safety | ERCPBelgium